SUVN-911

DRUG2 trials

Sponsors

Suven Life Sciences Limited

Conditions

Depressive Disorder, MajorMajor Depressive Disorder

Phase 1

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects

CompletedNCT03155503

Suven Life Sciences LimitedDepressive Disorder, Major

Start: 2017-05-22End: 2018-03-14Updated: 2018-05-29

Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects

CompletedNCT03551288

Suven Life Sciences LimitedMajor Depressive Disorder

Start: 2018-05-22End: 2018-07-16Updated: 2018-08-09

Related Papers

Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects.

2022-08-131 citations